Losartan Carboxaldehyde

CAS No. 114798-36-6

Losartan Carboxaldehyde( —— )

Catalog No. M21093 CAS No. 114798-36-6

Losartan Carboxaldehyde is an endothelial cyclooxygenase (COX)-2 inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 110 Get Quote
10MG 177 Get Quote
25MG 385 Get Quote
50MG 575 Get Quote
100MG 801 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Losartan Carboxaldehyde
  • Note
    Research use only, not for human use.
  • Brief Description
    Losartan Carboxaldehyde is an endothelial cyclooxygenase (COX)-2 inhibitor.
  • Description
    Losartan Carboxaldehyde is an endothelial cyclooxygenase (COX)-2 inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    COX
  • Recptor
    COX-2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    114798-36-6
  • Formula Weight
    420.8
  • Molecular Formula
    C22H21ClN6O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (296.99 mM)
  • SMILES
    CCCCc1nc(Cl)c(C=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Kramer C. Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179[J]. Circulation Research 2002 90(7):770-776.
molnova catalog
related products
  • Lornoxicam

    Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties.

  • Indobufen

    Indobufen is an inhibitor of platelet aggregation and is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes.

  • Etoricoxib

    Etoricoxib(MK-0663) selectively inhibited COX-2 in human whole blood assays in vitro, with an IC50 value of 1.1 ± 0.1 μM for COX-2 (LPS-induced prostaglandin E2 synthesis), compared with an IC50 value of 116 ± 8 μM for COX-1 (serum thromboxane B2 generation after clotting of the blood).